TME NEWS

Targeted Oncology Interview with Dr. Peter Beitsch - Study Reveals HER2 Breast Cancer Subtype Beneficial for Treatment Individualization

Study Reveals HER2 Breast Cancer Subtype Beneficial for Treatment Individualization

 Targeted Oncology Interview with Dr. Peter Beitsch

"I think it is going to make a major impact in the majority of triple-positive women and, probably, the subtyping should probably be routinely done on those patients who are triple-positive. This is to see if they are that luminal subtype, because they really need the pertuzumab/trastuzumab combination, even if it is in the adjuvant setting. I think this will have a major impact on women with HER2 disease.- Peter Beitsch, MD

Project details